The New York Times reports that genetic screening is increasingly offered as an employee benefit.
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
The consumer genomics firm says employer benefits programs could expand access to BRCA1/2, Lynch syndrome, and FH genetic testing in the general population.
Bioage Labs now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
The company plans to use proceeds to further invest in its development of molecular testing and other strategies in the preventive medicine space.
The latest offering puts the genetic testing company on the path toward becoming what it calls a preventive health service company.
The company has made agreements with two cancer diagnostics firms — GenomeDx, and Cynvenio — bundling its hereditary germline analysis with their somatic tests.
Based on evidence the company submitted on the test, and helped by its low pricing, Color also has preferred provider status with a number of plans.
The company, which has been offering its hereditary cancer risk test at a self-pay rate of around $250, will continue to work with insurers to grow in-network status.
Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.
In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.